2032년까지의 세계 아르테수네이트 주사제 시장 규모 및 전망

Global Artesunate Injection Market Size and Forecast till 2032

상품코드MRFRHC38057HCR
발행기관Market Research Future
발행일2025.05.22
페이지 수107 Pages
포맷PDF
커버리지Global

₩7,425,000 – ₩10,875,000

보고서 요약(국문)

전 세계 아르테수네이트 주사제 시장 조사 보고서: 순도별(아르테수네이트 0.99, 아르테수네이트 0.98), 적용 분야별(말라리아, 중증 말라리아, 뇌 말라리아, 단순 말라리아, 기타), 최종 사용자별(병원, 진료소, 약국, 정부 기관, 비정부 기구), 유통 채널별(직접 판매, 유통업체 및 도매업체, 소매 약국, 온라인 판매), 지역별(북미, 유럽, 아시아 태평양, 남미, 중동 및 아프리카)로 분류하여 2032년까지 예측합니다.

시장 개요
2023년 전 세계 아르테수네이트 주사제 시장은 약 8,500만 3,749.11달러의 매출을 기록했습니다. 전 세계 아르테수네이트 주사제 시장은 2024년부터 2032년까지 연평균 0.9%의 성장률을 기록할 것으로 예상됩니다.
전 세계 아르테수네이트 주사제 시장은 말라리아 발병률 증가, 신속 작용 주사 치료제에 대한 선호도 증가, 제조 및 유통 기술의 발전 등에 힘입어 성장하고 있습니다. 또한, 인식 제고 및 교육 활동 강화로 조기 진단 및 치료가 더욱 촉진되고 있습니다.
전 세계 아르테수네이트 주사제 시장은 높은 치료 비용, 제한적인 지역적 공급, 제품 승인을 지연시키는 규제 장벽 등 여러 가지 주요 제약 요인에 직면해 있습니다. 지적 재산권 및 특허 관련 복잡성은 시장 확장을 저해하는 요인이며, 다른 항말라리아 치료제와의 경쟁 또한 추가적인 위협으로 작용합니다.

이러한 제약에도 불구하고, 시장은 유망한 성장 잠재력을 지니고 있습니다. 원격 의료 서비스의 성장은 특히 농촌 및 말라리아 유행 지역에서 원격 진단과 시기적절한 아르테수네이트 주사 투여를 가능하게 합니다. 또한, 민관 협력을 통해 말라리아 연구 자금 지원이 확대되는 것도 중요한 역할을 하고 있습니다.

지역별 제조 허브의 출현은 공급망의 회복력을 강화하고, 전반적인 의료 인프라 발전은 주사 치료에 대한 접근성을 확대합니다. 이러한 요인들은 전 세계 아르테수네이트 주사제 시장에 상당한 영향을 미쳐 공급망 역학, 수요, 가격 추세에 변화를 가져옵니다.

시장 세분화
전 세계 아르테수네이트 주사제 시장은 순도에 따라 아르테수네이트 0.99와 아르테수네이트 0.98로 구분됩니다.
적용 분야에 따라 전 세계 아르테수네이트 주사제 시장은 말라리아, 중증 말라리아, 뇌 말라리아, 단순 말라리아, 기타 적용 분야로 세분화됩니다.
최종 사용자 측면에서 전 세계 아르테수네이트 주사제 시장은 병원, 진료소, 약국, 정부 기관, 비정부 기구로 나뉩니다.
유통 채널에 따라 전 세계 시장은 직접 판매, 유통업체 및 도매업체, 소매 약국, 온라인 판매로 분류됩니다.

지역별로 보면, 전 세계 아르테수네이트 주사제 시장은 북미, 유럽, 남미, 중동 및 아프리카, 아시아 태평양으로 구분됩니다.

지역 분석
북미 지역에서는 말라리아가 세계적인 보건 문제로 인식되고 있다는 점, 특히 풍토병 지역으로의 국제 여행 증가가 아르테수네이트 주사제 수요에 큰 영향을 미치고 있습니다. 미국과 캐나다는 말라리아가 자연적으로 발생하는 지역은 아니지만, 해외 유입 사례가 증가하면서 아르테수네이트와 같은 효과적인 치료제에 대한 수요가 증가하고 있습니다.
유럽에서는 유럽의약품청(EMA)이 중증 말라리아 치료에 있어 아르테수네이트의 효과를 인정하여 여러 국가에서 국가 치료 프로토콜에 포함시켰습니다. 그러나 엄격한 규제 요건과 높은 치료 비용은 여전히 ​​광범위한 사용을 가로막는 장벽으로 작용하고 있습니다.
아시아 태평양 지역에서는 세계보건기구(WHO)가 중증 말라리아의 1차 치료제로 아르테수네이트를 권장하면서 각국의 치료 정책에 상당한 영향을 미쳤고, 지역 전반에 걸쳐 아르테수네이트의 수용과 사용이 증가했습니다.

남미에서는 브라질, 페루, 콜롬비아와 같이 아마존 분지에 위치한 국가들이 높은 말라리아 전염률과 싸우고 있습니다. 아르테수네이트 주사제는 국가 치료 전략의 핵심 요소가 되었으며, 이는 중증 사례 관리에 있어 그 중요성을 강조합니다.
중앙아프리카, 특히 콩고민주공화국(DRC)과 주변 국가들은 말라리아로 가장 심각한 피해를 입은 지역 중 하나이며, 따라서 아르테수네이트는 이 지역의 의료 대응에 필수적인 치료제입니다.

주요 기업
AMIVAS, Advacare Pharma, Zydus Cadila, Intas Pharmaceutical, Systacare Remedies, Lexicare Pharma, Cipla, Guilin Pharma, IPCA Laboratories, Watran Pharmaceuticals Pvt. Ltd.는 글로벌 아르테수네이트 주사제 시장 조사에서 선도적인 기업입니다.

보고서 요약(영어 원문)

Global Artesunate Injection Market Research Report by Purity (Artesunate 0.99, Artesunate 0.98), by Application (Malaria, Severe Malaria, Cerebral Malaria, Uncomplicated Malaria, Other Applications), by End User (Hospitals, Clinics, Pharmacies, Government Institutions, Non-Governmental Organizations), by Distribution Channel (Direct Sales, Distributors and Wholesalers, Retail Pharmacies, and Online Sales), by Region (North America, Europe, APAC, South America, MEA) Forecast till 2032

Market Overview
In 2023, the global artesunate injection market generated a revenue of approximately USD 85,003,749.11. The global artesunate injection market is projected to experience with a compound annual growth rate (CAGR) of 0.9% between 2024 and 2032.
The global artesunate injection market is driven by the rising incidence of malaria, growing preference for fast-acting injectable treatments, and advancements in manufacturing and distribution. Increased awareness and educational efforts have further supported early diagnosis and treatment.
The global artesunate injection market faces several key restraints, including the high cost of treatment, limited regional availability, and regulatory hurdles that slow product approvals. Intellectual property and patent complexities further challenge market expansion, while competition from alternative antimalarial therapies poses an additional threat.
Despite these limitations, the market presents promising opportunities. The growth of telehealth services enables remote diagnosis and timely administration of artesunate injections, especially in rural and malaria-endemic regions. Public-private partnerships are also playing a vital role by increasing funding for malaria research.
The emergence of regional manufacturing hubs enhances supply chain resilience, while overall advancements in healthcare infrastructure support broader access to injectable treatments. These factors significantly impact the global artesunate injection market, influencing supply chain dynamics, shaping demand, and affecting pricing trends.

Market Segmentations
The purity type of the global artesunate injection market research comprises Artesunate 0.99 and Artesunate 0.98.
Based on the application type, the global artesunate injection market has been segmented into malaria, severe malaria, cerebral malaria, uncomplicated malaria, other applications.
In terms of end user, the global artesunate injection market is divided into hospitals, clinics, pharmacies, government institutions, non-governmental organizations.
Depending on the distribution channel, the global market has been categorized into direct sales, distributors and wholesalers, retail pharmacies, and online sales.
Based on regions, the global artesunate injection market includes north America, Europe, South America, Middle East & Africa, and Asia Pacific.

Regional Analysis
In North America, the demand for artesunate injections is largely influenced by growing awareness of malaria as a global health concern, particularly due to increased international travel to endemic regions. While malaria is not naturally present in the United States and Canada, the number of imported cases has risen, prompting a need for effective treatment options like artesunate.
Across Europe, the European Medicines Agency (EMA) has acknowledged artesunate’s effectiveness in treating severe malaria, resulting in its integration into national treatment protocols in several countries. However, strict regulatory requirements and high treatment costs continue to pose barriers to its widespread use.
In the Asia-Pacific region, the World Health Organization’s (WHO) endorsement of artesunate as the frontline treatment for severe malaria has significantly shaped national treatment policies, boosting its acceptance and usage throughout the region.
In South America, countries located within the Amazon basin, such as Brazil, Peru, and Colombia, continue to battle high malaria transmission rates. Artesunate injections have become a core component of national treatment strategies, emphasizing their importance in controlling severe cases.
Central Africa, particularly the Democratic Republic of the Congo (DRC) and surrounding nations, remains among the most severely affected by malaria, making artesunate a vital therapy in the region’s healthcare response.

Key Players
AMIVAS, Advacare Pharma, Zydus Cadila, Intas Pharmaceutical, Systacare Remedies, Lexicare Pharma, Cipla, Guilin Pharma, IPCA Laboratories, Watran Pharmaceuticals Pvt. Ltd. are the leading companies in the Global Artesunate Injection Market Research.

상세 목차

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ................................................................................................................. 16
2 MARKET INTRODUCTION ............................................................................................................. 18
2.1 DEFINITION .................................................................................................................................................................. 18
2.2 SCOPE OF THE STUDY .............................................................................................................................................. 18
2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 18
2.4 MARKET STRUCTURE .............................................................................................................................................. 19
3 RESEARCH METHODOLOGY ........................................................................................................ 20
3.1 OVERVIEW .................................................................................................................................................................... 20
3.2 DATA FLOW .................................................................................................................................................................. 22
3.2.1 DATA MINING PROCESS ....................................................................................................................................... 22
3.3 PURCHASED DATABASE: ......................................................................................................................................... 23
3.4 SECONDARY SOURCES: ............................................................................................................................................ 24
3.4.1 SECONDARY RESEARCH DATA FLOW: ....................................................................................................................... 25
3.5 PRIMARY RESEARCH: ............................................................................................................................................... 26
3.5.1 PRIMARY RESEARCH DATA FLOW: ....................................................................................................................... 27
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ........................................................................................ 28
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ............................................................................................................. 28
3.6 APPROACHES FOR MARKET END USER ESTIMATION: ............................................................................... 29
3.6.1 REVENUE ANALYSIS APPROACH ............................................................................................................................ 29
3.6.2 DATA FORECASTING ............................................................................................................................................. 30
3.6.3 DATA FORECASTING TECHNIQUE ............................................................................................................................ 30
3.7 DATA MODELING ........................................................................................................................................................ 31
3.7.1 MICROECONOMIC FACTOR ANALYSIS: ....................................................................................................................... 31
3.7.2 DATA MODELING: ............................................................................................................................................... 32
3.8 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 33
4 MARKET DYNAMICS ...................................................................................................................... 35
4.1 INTRODUCTION ........................................................................................................................................................... 35
4.2 DRIVERS ......................................................................................................................................................................... 37
4.2.1 INCREASING PREVALENCE OF MALARIA ..................................................................................................................... 37
4.2.2 GROWING DEMAND FOR INJECTABLE TREATMENTS ..................................................................................................... 37
4.2.3 ADVANCEMENTS IN MANUFACTURING AND DISTRIBUTION ............................................................................................. 37
4.2.4 GROWING AWARENESS AND EDUCATION .................................................................................................................. 38
4.3 RESTRAINTS ................................................................................................................................................................ 39
4.3.1 HIGH COST OF ARTESUNATE INJECTIONS ................................................................................................................... 39
4.3.2 LIMITED AVAILABILITY IN CERTAIN REGIONS ............................................................................................................... 39
4.3.3 REGULATORY CHALLENGES AND LENGTHY APPROVAL PROCESSES..................................................................................... 39
4.3.4 INTELLECTUAL PROPERTY AND PATENT ISSUES ............................................................................................................ 40
4.3.5 COMPETING ANTIMALARIAL THERAPIES ................................................................................................................... 40
4.4 OPPORTUNITY ............................................................................................................................................................. 41
4.4.1 EXPANSION OF TELEHEALTH SERVICES FOR REMOTE DIAGNOSIS AND TREATMENT ................................................................ 41
4.4.2 INCREASED PUBLIC-PRIVATE PARTNERSHIPS FOR FUNDING MALARIA RESEARCH ................................................................... 41
4.4.3 DEVELOPMENT OF COMBINATION THERAPIES TO ENHANCE TREATMENT EFFICACY .............................................................. 42
4.4.4 EMERGENCE OF REGIONAL MANUFACTURING HUBS TO BOOST SUPPLY CHAIN RESILIENCE ..................................................... 42
4.4.5 IMPACT ON OVERALL HEALTHCARE SECTOR ................................................................................................................ 42
4.4.6 IMPACT ON GLOBAL ARTESUNATE INJECTION MARKET ........................................................................................... 43
4.4.7 IMPACT ON THE SUPPLY CHAIN OF THE ARTESUNATE INJECTION MARKET .................................................... 43
4.4.8 IMPACT ON MARKET DEMAND OF ARTESUNATE INJECTION MARKET .............................................................. 43
4.4.9 IMPACT ON PRICING OF ARTESUNATE INJECTION MARKET............................................................................. 44
5 MARKET FACTOR ANALYSIS ........................................................................................................ 45
5.1 SUPPLY CHAIN ANALYSIS ..................................................................................................................................... 45
5.1.1 RAW MATERIAL SUPPLIERS ................................................................................................................................... 46
5.1.2 MANUFACTURING ................................................................................................................................................ 46
5.1.3 DISTRIBUTION AND LOGISTICS ............................................................................................................................. 46
5.1.4 RETAIL AND CONSUMPTION .................................................................................................................................. 46
5.2 PORTER’S FIVE FORCES MODEL ........................................................................................................................... 47
5.2.1 BARGAINING POWER OF SUPPLIERS ......................................................................................................................... 48
5.2.2 BARGAINING POWER OF BUYERS ............................................................................................................................ 48
5.2.3 THREAT OF NEW ENTRANTS ................................................................................................................................... 48
5.2.4 THREAT OF SUBSTITUTES ...................................................................................................................................... 48
5.2.5 INTENSITY OF RIVALRY .......................................................................................................................................... 49
6 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY......................................................... 51
6.1 INTRODUCTION ........................................................................................................................................................... 51
6.2 ARTESUNATE 0.99 ..................................................................................................................................................... 52
6.3 ARTESUNATE 0.98 ..................................................................................................................................................... 52
7 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION .............................................. 54
7.1 INTRODUCTION ........................................................................................................................................................... 54
7.1.1 MALARIA .......................................................................................................................................................... 56
7.1.2 SEVERE MALARIA ............................................................................................................................................... 56
7.1.3 CEREBRAL MALARIA ............................................................................................................................................. 56
7.1.4 UNCOMPLICATED MALARIA ................................................................................................................................... 56
8 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER ................................................... 58
8.1 INTRODUCTION ........................................................................................................................................................... 58
8.1.1 HOSPITALS ........................................................................................................................................................ 59
8.1.2 CLINICS ............................................................................................................................................................ 59
8.1.3 PHARMACIES .................................................................................................................................................... 59
8.1.4 GOVERNMENT INSTITUTIONS .................................................................................................................................. 60
8.1.5 NON-GOVERNMENTAL ORGANIZATIONS .................................................................................................................... 60
9 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL .......................... 61
9.1 INTRODUCTION ........................................................................................................................................................... 61
9.1.1 DIRECT SALES .................................................................................................................................................... 62
9.1.2 DISTRIBUTORS AND WHOLESALERS ........................................................................................................................... 62
9.1.3 RETAIL PHARMACIES ............................................................................................................................................ 62
9.1.4 ONLINE SALES .................................................................................................................................................... 63
10 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION ........................................................ 64
10.1 OVERVIEW .................................................................................................................................................................... 64
10.2 NORTH AMERICA ....................................................................................................................................................... 65
10.3 EUROPE .......................................................................................................................................................................... 71
10.4 ASIA PACIFIC ............................................................................................................................................................... 74
10.5 SOUTH AMERICA ....................................................................................................................................................... 77
10.6 MIDDLE EAST & AFRICA .......................................................................................................................................... 80
11 COMPETITIVE LANDSCAPE .......................................................................................................... 83
11.1 INTRODUCTION ........................................................................................................................................................... 83
11.2 MARKET SHARE ANALYSIS, 2023 ....................................................................................................................... 83
11.3 COMPETITOR DASHBOARD..................................................................................................................................... 84
11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 85
11.4.1 LAUNCH DEVELOPMENTS ................................................................................................................................... 85
12 COMPANY PROFILES .................................................................................................................... 86
12.1 AMIVAS ......................................................................................................................................................................... 86
12.1.1 COMPANY OVERVIEW ..................................................................................................................................... 86
12.1.2 TYPES OFFERED ............................................................................................................................................. 87
12.1.3 SWOT ANALYSIS ............................................................................................................................................ 87
12.1.4 KEY STRATEGY ................................................................................................................................................... 87
12.2 ADVACARE PHARMA ............................................................................................................................................... 88
12.2.1 COMPANY OVERVIEW ..................................................................................................................................... 88
12.2.2 TYPES OFFERED ............................................................................................................................................. 89
12.2.3 SWOT ANALYSIS ............................................................................................................................................ 89
12.2.4 KEY STRATEGY ................................................................................................................................................... 90
12.3 ZYDUS CADILA ............................................................................................................................................................ 91
12.3.1 COMPANY OVERVIEW ..................................................................................................................................... 91
12.3.2 TYPES OFFERED ............................................................................................................................................. 92
12.3.3 SWOT ANALYSIS ............................................................................................................................................ 92
12.3.4 KEY STRATEGY ................................................................................................................................................... 92
12.4 INTAS PHARMACEUTICAL ..................................................................................................................................... 93
12.4.1 COMPANY OVERVIEW ..................................................................................................................................... 93
12.4.2 TYPES OFFERED ............................................................................................................................................. 94
12.4.3 SWOT ANALYSIS ............................................................................................................................................ 94
12.4.4 KEY STRATEGY ................................................................................................................................................... 94
12.5 SYSTACARE REMEDIES ........................................................................................................................................... 95
12.5.1 COMPANY OVERVIEW ..................................................................................................................................... 95
12.5.2 TYPES OFFERED ............................................................................................................................................. 95
12.5.3 SWOT ANALYSIS ............................................................................................................................................ 96
12.5.4 KEY STRATEGY ................................................................................................................................................... 96
12.6 LEXICARE PHARMA .................................................................................................................................................. 97
12.6.1 COMPANY OVERVIEW ..................................................................................................................................... 97
12.6.2 TYPES OFFERED ............................................................................................................................................. 97
12.6.3 SWOT ANALYSIS ............................................................................................................................................ 98
12.7 CIPLA .............................................................................................................................................................................. 99
12.7.1 COMPANY OVERVIEW ..................................................................................................................................... 99
12.7.2 TYPES OFFERED ............................................................................................................................................. 99
12.7.3 SWOT ANALYSIS ............................................................................................................................................ 100
12.7.4 KEY STRATEGY ................................................................................................................................................... 100
12.8 GUILIN PHARMA ........................................................................................................................................................ 101
12.8.1 COMPANY OVERVIEW ..................................................................................................................................... 101
12.8.2 TYPES OFFERED ............................................................................................................................................. 101
12.8.3 SWOT ANALYSIS ............................................................................................................................................ 102
12.9 IPCA LABORATORIES ................................................................................................................................................ 103
12.9.1 COMPANY OVERVIEW ..................................................................................................................................... 103
12.9.2 TYPES OFFERED ............................................................................................................................................. 103
12.9.3 SWOT ANALYSIS ............................................................................................................................................ 104
12.10 WATRAN PHARMACEUTICALS PVT. LTD ........................................................................................................ 105
12.10.1 COMPANY OVERVIEW ..................................................................................................................................... 105
12.10.2 TYPES OFFERED ............................................................................................................................................. 105
12.10.3 SWOT ANALYSIS ............................................................................................................................................ 106

언급된 주요 기업들

AMIVAS, Advacare Pharma, Zydus Cadila, Intas Pharmaceutical, Systacare Remedies, Lexicare Pharma, Cipla, Guilin Pharma, IPCA Laboratories, Watran Pharmaceuticals Pvt. Ltd.

표 목록 (Tables)

LIST OF TABLES
TABLE 1 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD) 51
TABLE 2 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD) 55
TABLE 3 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD) 58
TABLE 4 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD) 61
TABLE 5 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION, 2018-2032 (USD) 64
TABLE 6 NORTH AMERICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD) 66
TABLE 7 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD) 66
TABLE 8 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD) 67
TABLE 9 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD) 67
TABLE 10 NORTH AMERICA ARTESUNATE INJECTION MARKET, DISTRIBUTION CHANNEL, 2018-2032 (USD) 67
TABLE 11 US ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD ) 68
TABLE 12 US: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD) 68
TABLE 13 US ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD) 68
TABLE 14 US ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD) 69
TABLE 15 CANADA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD ) 69
TABLE 16 CANADA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD ) 69
TABLE 17 CANADA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD ) 70
TABLE 18 CANADA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD ) 70
TABLE 19 EUROPE: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD ) 72
TABLE 20 EUROPE ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD ) 72
TABLE 21 EUROPE: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD ) 73
TABLE 22 EUROPE ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD ) 73
TABLE 23 EUROPE ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD ) 73
TABLE 24 ASIA PACIFIC: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD ) 75
TABLE 25 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD ) 76
TABLE 26 ASIA PACIFIC: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD ) 76
TABLE 27 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD ) 76
TABLE 28 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD ) 77
TABLE 29 SOUTH AMERICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD ) 78
TABLE 30 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD ) 78
TABLE 31 SOUTH AMERICA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD ) 79
TABLE 32 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD ) 79
TABLE 33 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD ) 79
TABLE 34 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD ) 81
TABLE 35 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD ) 81
TABLE 36 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD ) 81
TABLE 37 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD ) 81
TABLE 38 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD ) 82
TABLE 39 LAUNCH DEVELOPMENTS 85
TABLE 40 AMIVAS: PRODUCT OFFERED 87
TABLE 41 ADVACARE PHARMA: TYPES OFFERED 89
TABLE 42 ZYDUS CADILA: TYPES OFFERED 92
TABLE 43 INTAS PHARMACEUTICAL: TYPES OFFERED 94
TABLE 44 SYSTACARE REMEDIES: TYPES OFFERED 95
TABLE 45 LEXICARE PHARMA: TYPES OFFERED 97
TABLE 46 CIPLA: TYPES OFFERED 99
TABLE 47 GUILIN PHARMA: TYPES OFFERED 101
TABLE 48 IPCA LABORATORIES: TYPES OFFERED 103
TABLE 49 WATRAN PHARMACEUTICALS PVT. LTD: TYPES OFFERED 105

그림 목록 (Figures)

LIST OF FIGURES

FIGURE 1 GLOBAL ARTESUNATE INJECTION MARKET: STRUCTURE 19
FIGURE 2 GLOBAL ARTESUNATE INJECTION MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032) 36
FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2032) 38
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032) 41
FIGURE 5 SUPPLY CHAIN ANALYSIS: GLOBAL ARTESUNATE INJECTION MARKET 45
FIGURE 7 PORTER’S FIVE FORCES MODEL: GLOBAL ARTESUNATE INJECTION MARKET 47
FIGURE 8 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, SEGMENT ATTRACTIVENESS ANALYSIS 51
FIGURE 9 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, 2023 (% SHARE) 52
FIGURE 10 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, SEGMENT ATTRACTIVENESS ANALYSIS 54
FIGURE 11 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, 2023 (% SHARE) 55
FIGURE 12 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, SEGMENT ATTRACTIVENESS ANALYSIS 58
FIGURE 13 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, 2023 (% SHARE) 59
FIGURE 14 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, SEGMENT ATTRACTIVENESS ANALYSIS 61
FIGURE 15 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023 (% SHARE) 62
FIGURE 16 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION, 2023 (% SHARE) 64
FIGURE 17 NORTH AMERICAN MARKET: SWOT ANALYSIS 65
FIGURE 18 NORTH AMERICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE) 66
FIGURE 19 EUROPE MARKET: SWOT ANALYSIS 71
FIGURE 20 EUROPE: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE) 72
FIGURE 21 ASIA PACIFIC MARKET: SWOT ANALYSIS 74
FIGURE 22 ASIA PACIFIC: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE) 75
FIGURE 23 SOUTH AMERICA MARKET: SWOT ANALYSIS 77
FIGURE 24 SOUTH AMERICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE) 78
FIGURE 25 MIDDLE EAST & AFRICA MARKET: SWOT ANALYSIS 80
FIGURE 26 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE) 80
FIGURE 27 GLOBAL ARTESUNATE INJECTION PLAYERS: COMPETITIVE ANALSIS, 2023 83
FIGURE 28 COMPETITOR DASHBOARD: GLOBAL ARTESUNATE INJECTION 84
FIGURE 29 AMIVAS: SWOT ANALYSIS 87
FIGURE 30 ADVACARE PHARMA: SWOT ANALYSIS 89
FIGURE 31 ZYDUS CADILA: SWOT ANALYSIS 92
FIGURE 32 INTAS PHARMACEUTICAL: SWOT ANALYSIS 94
FIGURE 33 SYSTACARE REMEDIES: SWOT ANALYSIS 96
FIGURE 34 LEXICARE PHARMA: SWOT ANALYSIS 98
FIGURE 35 CIPLA: SWOT ANALYSIS 100
FIGURE 36 GUILIN PHARMA: SWOT ANALYSIS 102
FIGURE 37 IPCA LABORATORIES: SWOT ANALYSIS 104
FIGURE 38 WATRAN PHARMACEUTICALS PVT. LTD: SWOT ANALYSIS 106